Ipsen: Cabometyx approved by the FDA two months ahead of schedule

BUY-Top Picks, Fair Value EUR60 (+14%)
News published on April Tuesday 26, 2016
Share on

Ipsen’s recently partnered drug cabozantinib was approved yesterday in the US by the FDA in 2nd line RCC, well ahead of schedule. Top-line OS data are included in the press release (HR=0.66)

For more information, please contact marketing@bryangarnier.com

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities